Checkpoint inhibitors shrink tumors of metastatic bladder cancer patients
Combination immunotherapy is producing response rates ranging from 26 to 38 percent among patients with metastatic bladder cancer in the early stages of a three-arm clinical trial presented Saturday at the 2016 Society for Immunotherapy of Cancer (SITC) Annual Meeting in National Harbor, Maryland.
“Until the first, recent approval of immune checkpoint therapy, patients with bladder cancer have not had new treatment options for...
